title: Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.
abstract: We analyzed the effect of interferon α (IFN-α) and ribavirin (RBV) therapy on cell-associated human T-lymphotropic virus type 2 (HTLV-2) DNA in HIV-1-coinfected patients receiving antiretroviral therapy. Sixty-one patients under suppressive antiretroviral therapy were included: 37 with hepatitis C virus (HCV) infection, 15 with sustained virologic response (N = 10), relapse (N = 2), or with nonresponse (N = 3) after IFN-α/RBV treatment, and 9 with spontaneous HCV RNA clearance. Patients who were treated with IFN-α/RBV or had spontaneous HCV clearance had lower level of cell-associated HTLV-2 DNA (P = 0.022 and P = 0.040, respectively). Both IFN-alpha treatment and the ability to spontaneously clear HCV infection seem to reduce cell-associated HTLV-2 DNA in HIV-1-coinfected patients.
authors.affiliation: *Laboratory of Molecular Immunovirology, Department of Infectious Diseases, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain; and †Department of Infectious Diseases, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Abad-Fernández
authors.forename: Fernando
authors.initials: F
authors.lastname: Dronda
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: José Luis
authors.initials: JL
authors.lastname: Casado
authors.forename: María-Jesús
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Alejandro
authors.initials: A
authors.lastname: Vallejo
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004279:DNA, Viral / Q000302:isolation & purification*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000821:virology; D015497:HIV-1; D016174:Hepacivirus / Q000145:classification / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000821:virology; D015367:Human T-lymphotropic virus 2 / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000276:immunology*; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D016898:Interferon-alpha; D015850:Interleukin-6; D012367:RNA, Viral; D012254:Ribavirin